Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

DRIVIN CAR DRIVIN' CAR: Developing robust in vivo nanomedicine-based chimeric antigen receptor technology

Coordinator
Technische Universiteit Eindhoven, Netherlands
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
6 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101259068

What the project is doing

In the project's own words, from its summary on CORDIS.

DRIVIN’ CAR aims to transform immunotherapy by developing a scalable, cost-effective platform for in vivo generation of chimeric antigen receptor (CAR) immune cells. Using proprietary apolipoprotein nanoparticle (aNP) platform technology, DRIVIN’ CAR pursues robust CAR monocyte/macrophage (CAR M) and CAR T cell therapy. Owing to their biocompatibility and natural tropism for myeloid cells, aNPs are excellently suited for in vivo CAR M therapy.

For efficient in vivo T cell targeting, aNPs can be modularly surface-functionalized with apolipoprotein fusion proteins. The Program’s aNP platform technology addresses key limitations of current CAR therapies that prevent widespread implementation. It simultaneously tackles high treatment costs, complex ex vivo manufacturing procedures, and poor performance in solid tumors of conventional CAR cell therapy. The aNP platform also overcomes challenges associated with emerging in vivo approaches, such as limited specificity and safety risks.

By combining advanced bioengineering, high throughput manufacturing, library screening approaches and in vivo validation, DRIVIN’CAR brings together world-leading experts to deliver a unique and versatile platform for in vivo CAR therapies with real clinical impact. This Program’s successful completion will advance the aNP platform to TRL 4. Besides enabling in vivo CAR immune cell therapy for cancer treatment, the aNP platform has significant translational potential and pertinency for applications in non-malignant diseases such as autoimmune disorders and cardiovascular disease.

Topics

Who is involved

OrganisationCityCountryRole
Technische Universiteit EindhovenEindhovenNetherlandsCoordinator
Vrije Universiteit BrusselBruxelles / BrusselBelgiumParticipant
Universitaetsklinikum AachenAachenGermanyParticipant
Bio-Trip B.v.Bosch En DuinNetherlandsParticipant
Nanoworx B.v.EindhovenNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI